Is GOSS or GALT more profitable?

Galectin Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Company Net Margins Return on Equity Return on Assets Gossamer Bio -235.00% N/A -112.04% Galectin Therapeutics N/A N/A -176.83%

Does the media favor GOSS or GALT?

In the previous week, Gossamer Bio had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 5 mentions for Gossamer Bio and 3 mentions for Galectin Therapeutics. Gossamer Bio's average media sentiment score of 1.05 beat Galectin Therapeutics' score of 0.31 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GOSS or ANIK?

In the previous week, Gossamer Bio had 3 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for Gossamer Bio and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Gossamer Bio's score of 1.05 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is STRO or GOSS more profitable?

Gossamer Bio has a net margin of -235.00% compared to Sutro Biopharma's net margin of -395.25%. Company Net Margins Return on Equity Return on Assets Sutro Biopharma -395.25% N/A -88.12% Gossamer Bio -235.00% N/A -112.04%

Does the media favor STRO or GOSS?

In the previous week, Gossamer Bio had 3 more articles in the media than Sutro Biopharma. MarketBeat recorded 5 mentions for Gossamer Bio and 2 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.26 beat Gossamer Bio's score of 1.05 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, IFRX or GOSS?

InflaRx has higher earnings, but lower revenue than Gossamer Bio. InflaRx is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 7,614.12 -$51.63M -$0.58 N/A Gossamer Bio $48.47M 1.23 -$170.37M -$56.00 N/A

Is IFRX or GOSS more profitable?

InflaRx has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Gossamer Bio -235.00% N/A -112.04%

Does the media refer more to IFRX or GOSS?

In the previous week, Gossamer Bio had 3 more articles in the media than InflaRx. MarketBeat recorded 5 mentions for Gossamer Bio and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.60 beat Gossamer Bio's score of 1.05 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GOSS or EVMN more profitable?

Evommune has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Gossamer Bio -235.00% N/A -112.04% Evommune N/A -62.63% -40.55%

Does the media favor GOSS or EVMN?

In the previous week, Gossamer Bio had 3 more articles in the media than Evommune. MarketBeat recorded 5 mentions for Gossamer Bio and 2 mentions for Evommune. Gossamer Bio's average media sentiment score of 1.05 beat Evommune's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Gossamer Bio (GOSS) Competitors

$8.95 -0.81 (-8.26%)

As of 03:33 PM Eastern

Compare

GOSS vs. GALT, ANIK, STRO, IFRX, and EVMN

Should you buy Gossamer Bio stock or one of its competitors? Gossamer Bio's main competitors and comparable companies include Galectin Therapeutics (GALT), Anika Therapeutics (ANIK), Sutro Biopharma (STRO), InflaRx (IFRX), and Evommune (EVMN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gossamer Bio compare to Galectin Therapeutics?

Gossamer Bio (NASDAQ:GOSS) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

In the previous week, Gossamer Bio had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 5 mentions for Gossamer Bio and 3 mentions for Galectin Therapeutics. Gossamer Bio's average media sentiment score of 1.05 beat Galectin Therapeutics' score of 0.31 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Galectin Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Galectin Therapeutics	N/A	N/A	-176.83%

Gossamer Bio currently has a consensus target price of $256.00, indicating a potential upside of 2,522.95%. Galectin Therapeutics has a consensus target price of $11.00, indicating a potential upside of 198.10%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Gossamer Bio is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.23	-$170.37M	-$56.00	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

Gossamer Bio has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 4.2% of Gossamer Bio shares are owned by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Gossamer Bio beats Galectin Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Gossamer Bio compare to Anika Therapeutics?

Gossamer Bio (NASDAQ:GOSS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

In the previous week, Gossamer Bio had 3 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for Gossamer Bio and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Gossamer Bio's score of 1.05 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anika Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anika Therapeutics has a net margin of -3.14% compared to Gossamer Bio's net margin of -235.00%. Anika Therapeutics' return on equity of 0.20% beat Gossamer Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Anika Therapeutics	-3.14%	0.20%	0.15%

Gossamer Bio has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 4.2% of Gossamer Bio shares are held by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Anika Therapeutics has higher revenue and earnings than Gossamer Bio. Anika Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.23	-$170.37M	-$56.00	N/A
Anika Therapeutics	$112.82M	2.43	-$10.88M	-$0.27	N/A

Gossamer Bio presently has a consensus target price of $256.00, indicating a potential upside of 2,522.95%. Anika Therapeutics has a consensus target price of $22.00, indicating a potential upside of 7.16%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Gossamer Bio is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Anika Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Anika Therapeutics beats Gossamer Bio on 10 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to Sutro Biopharma?

Sutro Biopharma (NASDAQ:STRO) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 1.8% of Sutro Biopharma shares are owned by insiders. Comparatively, 4.2% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Gossamer Bio had 3 more articles in the media than Sutro Biopharma. MarketBeat recorded 5 mentions for Gossamer Bio and 2 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.26 beat Gossamer Bio's score of 1.05 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gossamer Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gossamer Bio has a net margin of -235.00% compared to Sutro Biopharma's net margin of -395.25%.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
Gossamer Bio	-235.00%	N/A	-112.04%

Sutro Biopharma has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

Gossamer Bio has lower revenue, but higher earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	1.78	-$191.09M	-$11.97	N/A
Gossamer Bio	$48.47M	1.23	-$170.37M	-$56.00	N/A

Sutro Biopharma presently has a consensus price target of $49.50, indicating a potential upside of 349.59%. Gossamer Bio has a consensus price target of $256.00, indicating a potential upside of 2,522.95%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Summary

Sutro Biopharma beats Gossamer Bio on 9 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

InflaRx has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Gossamer Bio	-235.00%	N/A	-112.04%

InflaRx has higher earnings, but lower revenue than Gossamer Bio. InflaRx is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,614.12	-$51.63M	-$0.58	N/A
Gossamer Bio	$48.47M	1.23	-$170.37M	-$56.00	N/A

InflaRx has a beta of 2.59, suggesting that its stock price is 159% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

42.4% of InflaRx shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 4.2% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

InflaRx currently has a consensus target price of $7.43, indicating a potential upside of 379.26%. Gossamer Bio has a consensus target price of $256.00, indicating a potential upside of 2,522.95%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

In the previous week, Gossamer Bio had 3 more articles in the media than InflaRx. MarketBeat recorded 5 mentions for Gossamer Bio and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.60 beat Gossamer Bio's score of 1.05 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Gossamer Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InflaRx beats Gossamer Bio on 10 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to Evommune?

Gossamer Bio (NASDAQ:GOSS) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

81.2% of Gossamer Bio shares are held by institutional investors. 4.2% of Gossamer Bio shares are held by insiders. Comparatively, 31.1% of Evommune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Evommune has lower revenue, but higher earnings than Gossamer Bio. Evommune is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.23	-$170.37M	-$56.00	N/A
Evommune	$10M	21.29	-$68.87M	-$11.03	N/A

In the previous week, Gossamer Bio had 3 more articles in the media than Evommune. MarketBeat recorded 5 mentions for Gossamer Bio and 2 mentions for Evommune. Gossamer Bio's average media sentiment score of 1.05 beat Evommune's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evommune has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Evommune	N/A	-62.63%	-40.55%

Gossamer Bio presently has a consensus target price of $256.00, suggesting a potential upside of 2,522.95%. Evommune has a consensus target price of $30.80, suggesting a potential upside of 425.15%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Evommune	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.69

Summary

Evommune beats Gossamer Bio on 9 of the 15 factors compared between the two stocks.

Get Gossamer Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOSS vs. The Competition

Export

Metric	Gossamer Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$54.66M	$3.90B	$7.29B	$12.91B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-0.16	12.96	275.68	25.25
Price / Sales	1.03	1,151.37	562.78	78.51
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	-0.21	16.59	10.54	5.92
Net Income	-$170.37M	-$22.69M	$3.50B	$381.16M
7 Day Performance	-12.04%	-6.38%	-4.13%	-4.32%
1 Month Performance	-16.32%	-14.15%	-8.51%	-7.19%
1 Year Performance	-95.30%	6.41%	2.12%	-4.99%

Gossamer Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOSS Gossamer Bio	2.9552 of 5 stars	$8.95 -8.3%	$256.00 +2,759.1%	-95.0%	$54.66M	$53.29M	N/A	162	News Coverage Analyst Forecast Gap Down
GALT Galectin Therapeutics	1.832 of 5 stars	$3.73 -4.4%	$11.00 +194.9%	-27.6%	$256.84M	N/A	N/A	9
ANIK Anika Therapeutics	3.3073 of 5 stars	$19.73 +3.3%	$22.00 +11.5%	+125.6%	$255.62M	$112.82M	N/A	235	Positive News
STRO Sutro Biopharma	3.5428 of 5 stars	$15.13 -1.4%	$49.50 +227.2%	+32.9%	$254.52M	$102.48M	N/A	128
IFRX InflaRx	2.1705 of 5 stars	$1.68 -2.3%	$7.43 +342.2%	+24.0%	$253.47M	$30K	N/A	65

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOSS) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gossamer Bio (GOSS) Competitors

GOSS vs. GALT, ANIK, STRO, IFRX, and EVMN

How does Gossamer Bio compare to Galectin Therapeutics?

Summary

How does Gossamer Bio compare to Anika Therapeutics?

Summary

How does Gossamer Bio compare to Sutro Biopharma?

Summary

How does Gossamer Bio compare to InflaRx?

Summary

How does Gossamer Bio compare to Evommune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gossamer Bio (GOSS) Competitors

GOSS vs. GALT, ANIK, STRO, IFRX, and EVMN

How does Gossamer Bio compare to Galectin Therapeutics?

Does the media favor GOSS or GALT?

Is GOSS or GALT more profitable?

Do analysts rate GOSS or GALT?

Which has better valuation and earnings, GOSS or GALT?

Which has more risk & volatility, GOSS or GALT?

Do institutionals & insiders believe in GOSS or GALT?

Summary

How does Gossamer Bio compare to Anika Therapeutics?

Does the media prefer GOSS or ANIK?

Is GOSS or ANIK more profitable?

Which has more volatility and risk, GOSS or ANIK?

Do institutionals and insiders believe in GOSS or ANIK?

Which has better earnings and valuation, GOSS or ANIK?

Do analysts prefer GOSS or ANIK?

Summary

How does Gossamer Bio compare to Sutro Biopharma?

Do insiders and institutionals believe in STRO or GOSS?

Does the media favor STRO or GOSS?

Is STRO or GOSS more profitable?

Which has more risk and volatility, STRO or GOSS?

Which has preferable valuation & earnings, STRO or GOSS?

Do analysts rate STRO or GOSS?

Summary

How does Gossamer Bio compare to InflaRx?

Is IFRX or GOSS more profitable?

Which has better valuation & earnings, IFRX or GOSS?

Which has more risk and volatility, IFRX or GOSS?

Do insiders & institutionals believe in IFRX or GOSS?

Do analysts prefer IFRX or GOSS?

Does the media refer more to IFRX or GOSS?

Summary

How does Gossamer Bio compare to Evommune?

Do institutionals and insiders have more ownership in GOSS or EVMN?

Which has stronger valuation and earnings, GOSS or EVMN?

Does the media favor GOSS or EVMN?

Is GOSS or EVMN more profitable?

Do analysts prefer GOSS or EVMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools